Smad4 promotes diabetic nephropathy by modulating glycolysis and OXPHOS
AuthorLi, J; Sun, YBY; Chen, W; Fan, J; Li, S; Qu, X; Chen, Q; Chen, R; Zhu, D; Zhang, J; ...
Source TitleEMBO Reports
University of Melbourne Author/sNilsson, Susan
Document TypeJournal Article
CitationsLi, J., Sun, Y. B. Y., Chen, W., Fan, J., Li, S., Qu, X., Chen, Q., Chen, R., Zhu, D., Zhang, J., Wu, Z., Chi, H., Crawford, S., Oorschot, V., Puelles, V. G., Kerr, P. G., Ren, Y., Nilsson, S. K., Christian, M. ,... Yu, X. (2020). Smad4 promotes diabetic nephropathy by modulating glycolysis and OXPHOS. EMBO REPORTS, 21 (2), https://doi.org/10.15252/embr.201948781.
Access StatusAccess this item via the Open Access location
Open Access URLAccepted version
Diabetic nephropathy (DN) is the leading cause of end-stage kidney disease. TGF-β1/Smad3 signalling plays a major pathological role in DN; however, the contribution of Smad4 has not been examined. Smad4 depletion in the kidney using anti-Smad4 locked nucleic acid halted progressive podocyte damage and glomerulosclerosis in mouse type 2 DN, suggesting a pathogenic role of Smad4 in podocytes. Smad4 is upregulated in human and mouse podocytes during DN. Conditional Smad4 deletion in podocytes protects mice from type 2 DN, independent of obesity. Mechanistically, hyperglycaemia induces Smad4 localization to mitochondria in podocytes, resulting in reduced glycolysis and oxidative phosphorylation and increased production of reactive oxygen species. This operates, in part, via direct binding of Smad4 to the glycolytic enzyme PKM2 and reducing the active tetrameric form of PKM2. In addition, Smad4 interacts with ATPIF1, causing a reduction in ATPIF1 degradation. In conclusion, we have discovered a mitochondrial mechanism by which Smad4 causes diabetic podocyte injury.
- Click on "Export Reference in RIS Format" and choose "open with... Endnote".
- Click on "Export Reference in RIS Format". Login to Refworks, go to References => Import References